Neurothera Labs (TSXV:NTLX) Total Assets: C$4.18 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NTLX Neurothera Labs Inc TSXV:NTLX
32 GF Score
Price C$0.33
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs Total Assets?

Neurothera Labs TSXV:NTLX +12.07% 32 Total Assets is C$4.18 Mil as of Dec. 2025. GuruFocus rates TSXV:NTLX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Neurothera Labs's Total Assets for the quarter that ended in Dec. 2025 was C$4.18 Mil.

During the past 12 months, Neurothera Labs's average Total Assets Growth Rate was -50.00% per year. During the past 3 years, the average Total Assets Growth Rate was -53.60% per year.

During the past 5 years, Neurothera Labs's highest 3-Year average Total Assets Growth Rate was -26.30%. The lowest was -53.60%. And the median was -39.95%.

Total Assets is connected with ROA %. Neurothera Labs's annualized ROA % for the quarter that ended in Dec. 2025 was 0.00%. Total Assets is also linked to Revenue through Asset Turnover. Neurothera Labs's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Neurothera Labs  (TSXV:NTLX) Total Assets Explanation

Total Assets is connected with ROA %.

Neurothera Labs's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jul. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (1.038+4.184)/ 2 )
=0/2.611
=0.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Neurothera Labs's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jul. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (1.038+4.184)/ 2 )
=0/2.611
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Neurothera Labs Total Assets Related Terms

Neurothera Labs Total Assets Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs Total Assets Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Total Assets
0.15 1.36 1.29 1.22 1.07

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 1.07 1.09 1.04 4.18
TSXV:NTLX
32GF Score
Neurothera Labs Inc TSXV:NTLX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Neurothera Labs's Total Assets for the fiscal year that ended in Jan. 2025 is calculated as

Total Assets=Total Equity (A: Jan. 2025 )+Total Liabilities (A: Jan. 2025 )
=0.918+0.155
=1.07

Neurothera Labs's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=0.894+3.29
=4.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of C$4.18 Mil mean?
Neurothera Labs (TSXV:NTLX) has a Total Assets of C$4.18 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Neurothera Labs and its competitors.
Is Neurothera Labs' Total Assets too high?
Neurothera Labs' current Total Assets is C$4.18 Mil. Overall, Neurothera Labs has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' Total Assets compare to LLY and JNJ?
Neurothera Labs' Total Assets of C$4.18 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Neurothera Labs and its competitors. Neurothera Labs's current Total Assets is C$4.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (TSXV:NTLX) has a current Total Assets of C$4.18 Mil. The current Total Assets is C$4.18 Mil. Neurothera Labs' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Neurothera Labs (TSXV:NTLX), the current Total Assets is C$4.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurothera Labs Business Description

Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score

Get the complete analysis for TSXV:NTLX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.33
Price